SHEN26 is an investigational new drug which is being evaluated by Shenzhen Kexing Pharmaceuticals for the treatment of COVID-2019. It is an RNA replicase inhibitor.[1][2]
Identifiers | |
---|---|
| |
PubChem CID | |
Chemical and physical data | |
Formula | C19H23N5O5 |
Molar mass | 401.423 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "SHEN 26". AdisInsight. Springer Nature Switzerland AG.
- ^ Sun C, Liu H, Ouyang Z, Ding J, Zhang Q, Ma H, et al. (May 2024). "Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects". Expert Opinion on Investigational Drugs. 33 (5): 533–542. doi:10.1080/13543784.2024.2347302. PMID 38662639.